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Global developmental delay/intellectual disability (DD/ID)with speech/language delay and behavioral problems
as the most affected domains was present in 44 participants, with additional epilepsy present in 35 and
movement disorder in 13. Treatment regimens included various combinations/dosages of creatine-
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Neurodevelopmental outcomepatients with severe DD/ID. Increase of cerebral creatine and decrease of plasma/CSF guanidinoacetate levels
were achieved by supplementation with creatine-monohydrate combined with high dosages of L-ornithine
and/or an arginine-restricted diet (250 mg/kg/d L-arginine). Therapywas associatedwith improvement or stabi-
lization of symptoms in all of the symptomatic cases. The 4 patients treated younger than 9 months had normal
or almost normal developmental outcomes. One with inconsistent compliance had a borderline IQ at age
8.6 years. An observational GAMT database will be essential to identify the best treatment to reduce plasma
guanidinoacetate levels and improve long-term outcomes.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Guanidinoacetate methyltransferase (GAMT) deficiency (MIM
601240) is an autosomal recessive inborn error of creatine synthesis,
which results in global developmental delay/intellectual disability
(DD/ID). Affected individuals exhibit marked impairment of expressive
speech, autistic features, and varying neurological manifestations,
including epilepsy and movement disorders [1,2]. GAMT (EC 2.1.1.2)
catalyzes the last step of creatine synthesis, facilitating transfer of a sin-
gle methyl group from S-adenosylmethionine to guanidinoacetate
(GAA) to form creatine and S-adenosylhomocysteine [3]. GAA is synthe-
sized from L-arginine and L-glycine via the activity of the enzyme AGAT
(Arginine:Glycine Amidinotransferase, EC 2.1.4.1). Biochemical features
of GAMT deficiency include creatine deficiency as well as accumulation
of GAA in brain and body fluids.
Oral supplementation of creatine (administered as creatine-
monohydrate) is used to restore cerebral creatine levels [3]. Strategies
to reduce GAA levels include substrate deprivation via an arginine-
restricted diet as well as competitive inhibition of AGAT activity via
high-dose L-ornithine supplementation [4–8]. Sodium benzoate has
been proposed as an additional approach to reduce the production of
GAA via conjugation with glycine to form hippuric acid which is rapidly
excreted by the kidneys [9–11].
Since GAMTdeficiencywasfirst described in 1994 [12],more than 50
patients have been reported in the literature [13], but no guidelines
have been established regarding the use of the various treatment strat-
egies. Knowledge is particularly limited with regard to the use and ef-
fectiveness of those strategies designed to reduce levels of GAA.
We report the results of an international survey among clinicians
focusing on therapeutic strategies applied to patients with GAMT
deficiency. In addition, we describe single case studies illustrating
individual long-term clinical outcomes and the effects of sequential
introduction to the various therapeutic strategies on plasma and CSF
GAA levels.2. Patients and results
2.1. International survey
Using Redcap software, we performed an online survey, among 26
clinicians from Canada, the United States, and Europe whowere identi-
fied as treating patients with GAMT deficiency. The survey included
questions about clinical and biochemical features of patients, therapeu-
tic strategies, and clinical and biochemical outcomes. The survey was
initiated in July 2011 and preliminary data on 22 patients were present-
ed at the Annual SSIEMSymposium inGeneva (August 30–September 2,
2011). Additional iterations of data collectionwere necessary because of
inconsistencies in the initial design of the RedCap survey (e.g. some sub-
menus of core questions did not allow the clinician to choose among all
possible modalities; numerous questionnaires came back with incom-
plete data entries) and by means of propaganda and personal contacts
of the investigators, additional patients could be recruited into the sur-
vey until May 2013. This study was approved by the Ethical Review
Board of British Columbia Children's Hospital, the institution from
which the survey was conducted.2.2. Study population
Data from 48 patients (21 females, 27 males) from 38 families have
been collected. 22 patients from 17 families had been reported previ-
ously either as single case reports or in case series [1,2,8,14–24].
2.3. Data collection
Biochemical genetic data collection included cerebral creatine, urine/
plasma/CSF GAA, and plasma ornithine and arginine prior and in re-
sponse to treatment, as well as GAMT mutations. Clinical data collection
included age and clinical presentation at diagnosis, type and duration of
treatment and changes (improvements) of the initial clinical presenta-
tions upon treatment. Criteria for clinical presentation [1] included the
degree of DD/ID, and type and degree of additional morbidities such as
speech/language, behavior, epilepsy, and movement disorder.
Because data from formal neurodevelopmental assessments were
not available for most of the patients, clinicians were asked to estimate
the degree of DD/ID based on clinical judgment [25] at the time the pa-
tient was diagnosed. Criteria assisting the clinician in the estimation of
thedegree of DD/ID included the number and severity of developmental
domains including expressive speech, self-supporting skills (toilet
training, food intake) and behavioral comorbidities (autistic, disruptive,
aggressive behavior) in patients older than 5 years; and progress in de-
velopmental milestones including speech/language, gross/fine motor
skills, cognition, and social/personal interaction in children younger
than 5 years. Roughly, patientswith severe impairment have limited in-
tellectual functions despite special support in school, and are not able to
live independently in adulthood, whereas patients with mild impair-
ment are able to achieve intellectual functions up to grade 3 to 6 levels,
and are able to live independently in adulthood [26].
Behaviors were classified as hyperactive, aggressive or autistic ac-
cording to clinicians' judgment. Epilepsy was considered as a) mild if
the patient had occasional (e.g. fever induced) seizures and/or was sei-
zure free upon pharmacological treatment; b) severe if the patient had
frequent seizures despite pharmacological treatment. Movement disor-
der was defined as dystonia, chorea, hemiballism, ataxia, and spasticity.
Table 1 shows clinical and molecular features at the time of diagno-
sis/treatment start and changes of baseline features upon the various
treatment modalities in 48 patients with GAMT deficiency.
2.4. Clinical presentation at time of diagnosis
44 patients, all treated later than 9 months of age, including 2 pa-
tients who never received treatment, had DD/ID. Based on the criteria
outlined above, 25 patients were determined to have severe DD/ID
and 23 of them (92%) had additional problems such as epilepsy and/or
movement disorder; 19 patients were found to have mild/moderate
DD/ID, and 12 of them (63%) had additional problems such as epilepsy
and/or movement disorder. Borderline DD/ID was evident in 2 patients
treated since 9 months and 3 weeks of age, and normal development
was evident in the 2 patients treated since shortly after birth or
prenatally.
Of the 35 individuals with epilepsy, 23 had mild and 12 had severe
epilepsy. Severe epilepsy only occurred in patients who had severe
DD/ID.
Table 1
Clinical characteristics, treatment modalities and outcomes in 48 patients with GAMT deficiency.
Patient #
(ref)








1 (24) 1 (sibling P5) f c.327GNA/c.522GNA Prenatal Normal (nf) nd cr, orn-hd, diet-lp 41 mo Normal (nf)
2 (28) 2 (sibling P25) m c.299_c.311 dup13/c.233TNA 1 week Normal (nf) nd cr, orn-hd, diet-lp, benz 14 mo Normal (nf)
3 (15, 24) 3 (sibling P17) f c.152ANC/c.526dupG 3 weeks Normal (nf) n cr1orn-hd", diet-ar2 diet-pm, benz" "
interrupted treatment
7 y Normal 31 mo (f)
boderline 8 y (f)
4 4 (sibling P27) f 327GNA 9 mo Borderline (nf) n cr, orn-hd, diet-ar" ", diet-lp, benz 21 mo dd (dd,s)
5 (2) 1 (index sibling P1) m c.327GNA/c.522GNA 10 mo Mild (nf) e y cr, orn-hd, diet-lp 39 mo dd,e
6 (28) 5 m c.327GNA/c.522GNA 11 mo Moderate (nf) e y cr, orn-hd, diet-lp, benz 48 mo dd (dd,s),e
7 6 f Not determined 14 mo Mild (f) e y cr, orn-hd, SAM 7 y 4 mo dd
8 (28) 7 f c.327GNA/c.403GNA 15 mo Severe (nf) e y cr, orn-hd, diet-lp 8 y 6 mo dd (dd,b),e
9 (2) 8 m c.327GNA/c.36_c.37ins26 16 mo Moderate (nf) e y cr, orn-ld, diet-lp 36 mo dd (dd,s),e
10 9 m c.327GNA 17 mo Moderate (nf) m y cr 6 y 6 mo dd (dd,s,b),m
11 (16) 10 m c.503ANC 19 mo Mild (f) n cr, orn-ld 36 mo dd (dd,s)
12 (1, 18) 11 (sibling P19) f c.327GNA/c.48CNA 21 mo Mild (nf) m, e y cr, orn-hd 6 y 7 mo m,e
13 (14) 12 f c.327GNA 21 mo Moderate (f) n cr, orn-hd, diet-ar 39 mo dd (dd,s,b)
14 (3) 13 m c.327GNA/c.309dup13 22 mo Severe (nf) m, ee y cr, orn-hd" " " 16 y e,m
15 (17) 14 f c.327GNA/c.522GNA 24 mo Severe (nf) m, e y cr, orn-hd, diet-ar 10 y dd,e,m
16 15 m c.526dupG 24 mo Moderate (nf) n cr 44 mo dd
17 (1, 18) 3 (index sibling P3) m c.152ANC/c.526dupG 30 mo Mild (f) e n cr", orn-hd", diet-ar" ", benz" later diet-pm 10 y dd (dd,s),e
18 (1) 16 m Not reported 36 mo Severe (nf) ee n cr, orn-hd 36 mo dd (dd,s,b), e
19 11 (index sibling P12) m c.327GNA/c.48CNA 38 mo Moderate (nf) y cr,orn-hd 6 y 7 mo dd
20 (19) 17 m c.491insG/IVS5-3CNG 39 mo Severe (nf) m, e y cr, orn-ld" ", orn-hd, diet-lp" ", diet-ar 11 y dd, e,m
21 18 f c.327GNA 39 mo Severe (nf) m, ee y cr 48 mo dd (b)
22 (21, 22) 19 m c.497TNC 44 mo Mild (tbq = 55) (f) n cr, orn-hd 7 y 4 mo dd (dd,s,b) (IQ = 90)
23 20 m c.506GNA 48 mo Mild (f) n cr, orn-hd 3 y 9 mo dd (s)
24 21 m c.327GNA/c.133TNA 4 y 6 mo Severe (nf) m, e n cr, orn-hd 20 mo dd (dd,b), e,m
25 (28) 2 (index sibling P2) f c.299_c.311dup13/c.233TNA 5 y 6 mo Moderate (nf) e n cr, orn-hd, diet-lp 30 mo dd (dd,s,b),e
26 22 m c.522GNA/c.505TNC 5 y 7 mo Severe (nf) ee y cr, orn-hd, diet-lp 30 mo Stable
27 4 (index sibling P4) m c.327GNA 5 y 9 mo Moderate (nf) e n cr, orn-hd, diet-ar" ", diet lp, benz 21 mo dd (b)
28 23 (sibling P37) f Not reported 6 y 9 m0 Mild ee nd cr, orn-ld, diet-lp 26 mo dd(b), e
29 (23) 24 (cousin P47, P48) m c.59GNC 8 y Severe (nf) m, e nd cr, orn-ld" " ", diet-pm 7 y dd, m
30 25 f c.327GNA 8 y 6 mo Severe (f) ee n cr, orn-hd, diet-ar 48 mo dd (dd,s,b), e
31 26 f c.327GNA 9 y 3 mo Moderate (nf) e y cr 36 mo Stable
32 (20) 27 f c.590TNC 10 y Severe (f) e n cr, orn-hd, diet-ar 5 y then diet-lp 7 y dd,e
33 28 m c.327GNA 11 y Severe (nf) ee y cr 48 mo dd (b),e
34 29 f Not determined 11 y Severe (nf) n cr 12 mo Stable
35 30 m Not reported 12 y Severe (nf) ee n cr, orn-hd, diet-lp" " " 8 y id (s,b),e
36 31 f c.59GNC/c.521GNA 13 y Severe (f) nd cr, orn-ld" ", diet-lp" " 6 y dd
37 23 (index sibling P28) m Not reported 13 y 9 mo Moderate ee nd cr, orn-ld, diet-lp 26 mo dd(s), e
38 32 m c.289CNT 14 y Severe (nf) ee n cr, orn-hd, diet-lp 4 y id (b),e
39 (1) 33 (sibling P42) m c.59GNC 16 y Severe (f) m, e y cr 9 y e
40 34 f Not reported 18 y Severe (nf) ee n cr, orn-hd, diet-lp" " " 8 y id (s,b),e
41 (23) 35 f c.506GNA 19 y Severe (nf) m, e nd no treatment 0 nd
42 (1) 33 (sibling 39) m c.59GNC 20 y Severe (f) e y cr 9 y e
43 (1) 36 (sibling P45) m c.59GNC 20 y Severe (f) e y cr 9 y e
44 37 f c.327GNA 21 y Severe (nf) m, ee n cr, orn-hd 11 mo dd (b), e
45 (1) 36 (sibling P43) m c.59GNC 22 y Severe (f) e nd cr 9 y e
46 38 m c.327GNA 25 y Moderate (nf) n No treatment 0 nd
47 (23) 24 (sibling P46) f c.59GNC 31 y Severe (nf) m, e nd cr, diet-pm 5 y m
48 (23) 2 (index sibling P45) f c.59GNC 34 y Severe (nf) m, e nd cr, diet-pm 5 y Stable
b: behavior; benz: sodium benzoate (100 mg/kg/d); cr: creatine-monohydrate (300–800 mg/kg); dd/id: developmental delay/intellectual disability; diet-ar: arginine-restricted diet (below DRI needing amino acid supplements); diet-lp: diet low
protein (meeting DRI without amino acid formula); diet-pm: protein modified diet avoiding protein rich foods such as meat andmilk products, no counting of protein intake); e: mild epilepsy; ee: severe epilepsy; (f): formal assessment; m: move-
ment disorder; mo: months; n: no; nd: not determined; (nf): no formal assessment; orn-hd: L-ornithine high dose (N200–800 mg/kg); orn-ld: L-ornithine low dose (100–200 mg/kg/); P: patient; (ref): reference; s: speech; SAM: S-Adenosyl-L-














19S. Stockler-Ipsiroglu et al. / Molecular Genetics and Metabolism 111 (2014) 16–2513 patients had a movement disorder and in 12 it occurred in associ-
ation with DD/ID and epilepsy. Patient 24 had intermittent (fever/illness
induced) episodes of ataxia lasting for days and slowly remitting after
the insult, a presentation not described in GAMT deficiency before.
2.5. Age at diagnosis/treatment onset
The median age at diagnosis was 51 months (range: prenatal/neo-
natal — 34 years). Patients with mild and moderate DD/ID were youn-
ger at treatment onset (median age at treatment start: 25.5 and
39 months) compared to thosewith severe DD/ID (median age at treat-
ment start: 132 months = 11 years). 4 patients who began treatment
prior to 9 months of age had either normal or borderline developmental
outcomes. Preliminary descriptive analysis suggests a positive relation-
ship between mean age at treatment onset and the degree of DD/ID
(Fig. 1).
2.6. Treatment
Various treatment strategies were employed in various combina-
tions and with various dosages. Creatine-monohydrate was given in
dosages of 300–800 mg/kg/d. L-Ornithine was given as L-ornithine
aspartate or L-ornithine hydrochloride, either in low dosages (orn-ld,
100–200 mg/kg/d) (as traditionally given for treatment of urea cycle
defects), or in higher dosages (orn-hd, 300–800 mg/kg/d; 400 mg/kg
being the target in most cases). Sodium benzoate was given at
100 mg/kg.
46 patients were treated and received creatine-monohydrate as
a common denominator. 10 received it as mono-therapy and 2 in com-
bination with the recommendation to avoid protein rich food such as
meat and dairy products. 9 patients received a combination of
creatine-monohydrate with L-ornithine; 25 received a combination of
creatine-monohydrate with L-ornithine and a medical diet aiming to
reduce arginine intake. L-Ornithine was given in a high dose in 27 andFig. 1.Mean ages at diagnosis/treatment onset and severity of developmental delay/intel-
lectual disability (DD/ID) in 48 patients with GAMT deficiency. (a) normal development
(n = 2): min age = 0 months (treatment started prenatally), max age = 0.23 months
(1 week); 25th, 50th, 75th percentile = 0, 0.12, 0.23 months. (b) borderline DD/ID
(n = 2): min age = 0.68 months (3 weeks), max age = 9 months; 25th, 50th, 75th
percentiles = 0.69, 4.9, 9 months. (c) mild DD/ID (n = 8): min age = 10.0 months,
max age = 81 months; 25th, 50th, 75th percentiles = 16.5, 25.5, 46 months. (d)moder-
ate DD/ID (n = 11): min age = 11 months, max age = 300 months; 25th, 50th, 75th
percentiles = 17, 39, 87 months. (e) severe DD/ID (n = 25): min age = 15 months,
max age = 408 months; 25th, 50th, 75th percentiles = 54, 132, 228 months. More
data are required for statistical analysis, exploring the possible causative effect of time of
treatment onset on developmental outcomes, controlling for various confounding factors.in a lowdose in 7 patients. 6 patients received additional sodiumbenzo-
ate. 1 patient received S-adenosylmethionine in combination with
creatine-monohydrate and high-dose or low-dose L-ornithine.
Diet was given in 3 different modalities: 1) a very low protein diet
restricting L-arginine intake to approximately 250 mg/kg/d and provid-
ing between 0.2 and 0.5 mg/kg natural protein together with arginine-
free amino acid formula to meet DRIs for protein intake (diet-arg); 2) a
low protein diet providing 0.6–1.8 g/kg natural protein together with
an arginine-free amino acid formula to meet DRIs for protein intake
(diet-lp); 3) a protein-modified diet avoiding protein rich food such as
meat andmeat products, but without counting protein intake andwith-
out arginine-free amino acid formula (diet-pm). 11 patients received
diet-arg, and 5 of them changed to a less strict protein restriction
(diet-lp, diet-pm) during the course of their treatment. 9 patients
received diet-lp, and one of them was switched to diet-arg later on. 3
patients received diet-pm.
Treatment duration was between 11 and 192 months (median 48,
mean 64.1).2.7. Treatment effects
Clinical improvement was achieved in the majority of patients.
Patient 37 became more interactive when his seizures were resolved
with treatment, but then showed oppositional and sometimes violent
behavior. Significant improvement was achieved on psychostimulant
medication.
Improvements were noted in several domains of DD/ID (behavior,
language and self-supportive skills/‘activities of daily life’, information
being mostly based on clinical judgment and third party informants),
as well as in epilepsy and movement disorder. Improvements were
achieved in patientswith severe,moderate andmild DD/ID, irrespective
of the treatmentmodality. Notably, a significant improvement of DD/ID
was objectified in patient 22 by an increase of the IQ (Reynell TBQ) of
55 at treatment start (age 44 months) to 90 after 48 months of
treatment (age 7 y 8 m).2.8. Magnetic resonance imaging (MRI)/proton magnetic resonance
spectroscopy (MRS)
38 patients underwent a brain MRI/MRS at the time of diagnosis. 18
had T2 signal hyperintensities of the basal ganglia (especially the globus
pallidus), in the rest specific MRI findings were not reported. 16 had
follow-upMRI upon treatment and basal ganglia changeswere reversed
in all of them. Brain creatine deficiency was confirmed in all 38 patients
on brain MRS at the time of diagnosis. In the 30 patients who had
follow-upMRS upon treatment, brain creatine levels were considerably
higher compared to baseline levels (no quantitative values available).2.9. Biomarkers
Urinary and/or plasma GAA levels were determined in all patients
prior to treatment and were elevated in all of them. A decrease, but
not normalization of elevated GAA levels, was evident in all 35 patients,
who had at least 1 measurement upon treatment. GAA levels in CSF
weremeasured in 8 patients prior to treatment. A decrease, but not nor-
malization was evident in the 4 patients who had a second lumbar
puncture upon treatment. Longitudinal data on plasma GAA, creatine,
ornithine and arginine levels in response to treatments were available
from Patients 1, 5, 13, 14 and 44. Fig. 2 shows cumulative data from
these patients upon the various treatment modalities. Systematic
monitoring of biomarkers in relation to time and modality of treatment
occurred in patients 13 and 44. Individual data of both patients are
shown in Figs. 3 and 4.
Fig. 2. Cumulative data (scattered blot) on plasma biomarker levels (guanidinoacetate [GAA], creatine, ornithine, arginine) in 5 patients (Patients 1, 5, 13, 14, 44) with GAMT deficiency in
relation to various treatmentmodalities. Numbers 1, 5, 13, 14, and 42 refer to values assigned to respective patients. Patient 1 received creatine-monohydrate (300 mg/kg/d), L-ornithine
(300 mg/kg/d), andprotein restricteddiet (1.0–1.4 g/kg natural protein and 0.5–0.7 g/kg/d from arginine free essential amino acid formula). Data represent a 33 month-treatmentperiod.
No baseline levels available. Patient 5 received creatine-monohydrate (400 mg/kg/d), L-ornithine (400 mg/kg/d), and protein restricted diet (0.5 g/kg natural protein and 0.5–0.7 g/kg/d).
Data represent a 20 month-treatment period. No baseline values available. Patient 14 received creatine-monohydrate (400 mg/kg/d) asmono-therapy overmost of his 16 treatment years
and L-ornithine (400 mg/kg/d) for 6 months. GAA levelsweremeasured only occasionally. Treatments of Patients 13 and44 are described in the respective case studies and in Figs. 3 and 4.
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Of the 82 known/reported alleles, 30 were c.327GNA (p.K109K,
splice site exon 2), occurring in 26 families. 15 alleles were c.59GNC
(p.W20S) and they occurred exclusively in Portuguese (n = 7) families.
The remaining mutations occurred in b3 alleles.
2.11. Case studies
2.11.1. Patient 14
2.11.1.1. Potentials and limitations of creatine mono-therapy. Treatment
with creatine-monohydrate (400 mg/kg/d) was initiated in this male
patient with global DD at 22 months. After 12 months of treatment
his hemiballistic movements and head drop seizures resolved, and his
basal ganglia changes and EEG normalized [3]. He was able to walk at
age 4 years, but he remained non-verbal and did not catch up with his
cognitive delay. At age 18 years he had severe ID, was not able to
speak a single word, and demonstrated hyperactive, erratic behavior.
Hewas toilet trained, fed himself with a spoon andwas able to ride a tri-
cycle and to recognize his parents and siblings. Additional L-ornithine
(400 mg/kg/d) at the age of 17.5 years did not result in clinical im-
provement. After six months, plasma GAA and ornithine levels were
12.2 μmol/L (baseline 19.1) (normal b 6.9) and 121 μmol/L (baseline54) (normal: 23–136 μmol/L) respectively. He developed a spontane-
ous tremor in his hands, which resolved when L-ornithine was
discontinued after 6 months.
2.11.2. Patient 44
2.11.2.1. Biomarkers and clinical outcomes after sequential introduction of
creatine and high dose L-ornithine. In this femalewith severe ID diagnosis
of GAMT deficiency was established at the age of 21 years. She was not
toilet trained, was unable to feed herself, and had progressive dystonia
and intractable epilepsy (10 seizures per month). Plasma GAA, creatine,
ornithine and arginine levels during 10 months of treatment are shown
in Fig. 3. Seizure frequency decreased with creatine-monohydrate
therapy (400 mg/kg/d). She became seizure-free upon additional
L-ornithine (400 mg/kg/d) and caregivers reported improvement in at-
tention and less sleepiness. She developed loose stools and an increased
frequency of bowel movements during the first weeks of L-ornithine
supplementation.
2.11.3. Patient 13
2.11.3.1. Biomarkers and clinical outcomes after sequential introduction of
creatine, high dose ornithine and arginine restricted dietary treatment. In
this female patient with global DD, diagnosis of GAMT deficiency was
Fig. 3. Patient 44. Effect of the various treatment strategies (creatine-monohydrate [400 mg/kg/d] and L-ornithine [400 mg/kg/d]), on plasma levels of guanidinoacetate (GAA)
(A); creatine (B); arginine and ornithine (C).
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monohydrate (400 mg/kg/d), L-ornithine (400 mg/kg/d), and an
arginine-restricted diet (260–270 mg arginine/d, 0.3 g/kg/d protein,
supplemented with an arginine-free essential amino acid formula for a
total protein intake of 1.5 g/kg/d) were sequentially introduced. Brain
creatine levels almost normalized after 24 months of treatment with
creatine-monohydrate.
Plasma GAA, creatine, ornithine and arginine levels during
46 months of treatment are shown in Fig. 4. Notably, plasma and
CSF GAA levels decreased from 20-fold to 2-fold and from 100-foldto 10-fold respectively, compared to the upper limit of normal (in-
terim data on this patient have partly been published in [14]).
Growth continued at the 85th and 90th percentiles for weight and
height. At 60 months, after 3 years of this treatment, the caregiver
report suggested improved attention and social skills. Non-Verbal
IQ was at the 5th percentile (WPPSI-III). Visual motor, global adap-
tive and single word receptive language abilities were at or below
the 1st percentile on standard measures. Recognition knowledge of
basic concepts (colors, numbers, letters, shapes) was in the average
range (37th percentile).
Fig. 4. Patient 13. Effect of the various treatment strategies (creatine-monohydrate [400 mg/kg/d], L-ornithine [400 mg/kg/d], arginine-restricted diet [260–270 mg arginine /d; 0.2–0.3 g
natural protein/kg/d, supplemented with arginine-free essential amino acid formula for a total protein intake of 1.5 g/kg/d]) on A) guanidinoacetate (GAA) levels in plasma and cerebro-
spinal fluid (CSF); and plasma levels of creatine (B); arginine and ornithine (C).
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2.11.4.1. Challenging compliance and adverse effects of treatment interrup-
tion. Treatment was started within the first 3 weeks of life, with
creatine-monohydrate (400 mg/kg/d), high dose L-ornithine (400–
800 mg/kg), an arginine-restricted diet (0.6 g/kg/d natural pro-
tein), and sodium benzoate (100 mg/kg). At 32 months her devel-
opment was age appropriate with an MDI (mental developmentalindex) of 91 (normal 100 +/− 14), while her late treated older
brother (Patient 17) had global developmental at a comparable
age [18]. Interim data on this patient until age 32 months have
been published in [15]). At age 4 years, the parents stopped her
treatment. Treatment was recommenced at age 5 years when she
had a febrile seizure, but compliance was questionable. At age
7 years sodium benzoate and arginine/protein restricted diet were
discontinued. Currently, at age 8.6 years her IQ is 71 (HAWIK IV).
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apy has an IQ of 68 at age 13 years. Data on biomarkers (GAA, cre-
atine) are not available.
3. Discussion
The main purpose of this survey was to obtain information about
current therapeutic practices and outcome surveillance in patients
with GAMT deficiency. Different treatment strategies are used in differ-
ent centers ranging from creatine-monohydratemono-therapy directed
at correcting cerebral creatine deficiency to combinations of one or
more other strategies directed at reducing accumulation of toxic GAA.
Creatine-monohydrate supplementation had an appreciable effect
on the correction of reduced cerebral creatine levels as shown in the
30patientswhohad follow-up brainMRS. The 10patientswho received
creatine as mono-therapy throughout their treated lifetime, showed
mainly improvements in epilepsy and movement disorder. Creatine-
monohydrate seems to be less efficient for improvement of cognitive/
intellectual abilities. Limitations are shown in Patient 14 (case study)
who had been on mono-therapy with creatine-monohydrate for most
of his 16-year treatment period. Although his neurologic signs and
symptoms (epilepsy, movement disorder, basal ganglia changes) re-
solved, at the age of 18 years he had severe ID, was non-verbal and
demonstrated autistic/aggressive behavior. Another example which
illustrates the limitations of mono-therapy with creatine, is the child
reported by Schulze et al. [6], whose intractable epilepsy was only
controlled when an arginine-restricted diet with (low-dose) ornithine
was given in addition to creatine-monohydrate [7].
Additional treatment modalities aiming at reducing GAA accumula-
tion can potentially improve outcomes. The observations in Patients 13
and 44 (case studies) show that a strong reduction of GAA levels is
possible through adding L-ornithine to the treatment. While an initial
40–50% reduction of baseline plasma GAA levels was achieved by
creatine mono-therapy, a further (36–50%) reduction of plasma GAA
concentration was achieved by high dose L-ornithine supplementation
(400 mg/kg/d) in both patients. A reduction of AGAT expression by
high concentrations of creatine and inhibition of AGAT activity by high
intracellular concentrations of L-ornithine is one explanation for these
findings [27]. Another explanation is that the high ornithine and the
low arginine and glycine concentrations achieved by these treatment
modalities, reverse AGAT activity by mass action, thus resulting in
decreased production of GAA.
It is currently believed that the GAA reducing effect of L-ornithine is
best achieved by dosages of 400-800 mg/kg/d. Lower dosages of
L-ornithine (100–200 mg/kg/d), as traditionally given for treatment of
urea cycle defects, might not result in high enough tissue ornithine
levels required for suppression of AGAT activity. The wide range of
plasma ornithine levels observed in our patients during L-ornithine sup-
plementation (from lower to beyond the upper normal range), suggests
a fast and complete clearance of peak blood ornithine levels after
L-ornithine ingestion. To obtain reproducible data, sample collection
should occur at defined intervals from L-ornithine intake.
Dietary protein restriction was used in a proportion of patients to
further reduce GAA levels via restriction of arginine, which is an essen-
tial substrate for GAA synthesis. In Patient 13 (Fig. 4A) an additional de-
crease of plasma GAA levels was achieved when an arginine restricted
diet was added to the ongoing creatine-monohydrate and L-ornithine
treatment. The diet employed in this patient implies an arduous protein
restriction (allowing for only 0.2–0.3 g per kilo of daily natural protein
intake) and adherence is doubtlessly challenging. 5 of the 11 patients
who initially started on a similar, arginine restricted diet, continued on
a less restricted diet during the course of their treatment. 9 patients
were started on a moderate protein restriction (0.8–1.5 g/kg/d) from
the beginning, however data allowing the determination of the GAA
lowering effect of moderate protein restriction are not available from
these patients.In their most recent study, including 5 patients with GAMT deficien-
cy (4 of them are included in this study as Patients 2, 6, 8, 25), Viau et al.
[28] are showing a strong correlation of plasma arginine and ornithine
levels. Based on this observation they hypothesize that L-ornithine not
only suppresses AGAT activity, but at the same time stimulates arginine
production and thus reduces the arginine and GAA lowering effect
achieved by an arginine-restricted diet. The authors also show a strong
correlation between plasma glycine and GAA levels, suggesting that the
glycine lowering effect of sodium benzoate might be a particularly
effective treatment strategy.
S-adenosyl methionine (SAM) might enhance residual GAMT activ-
ity inmutations affecting the SAMbinding site. In our series only patient
7 received SAM, however, enzymatic studies, e.g. in patient fibroblasts,
to prove the effect of SAM, have not been performed in this patient.
Concentrations of metabolites in CSF reflect the effects of treatment
on the cerebral pathophysiology more directly. In Patient 13, CSF GAA
levels decreased by almost 90% from baseline, but despite multiple
treatment modalities, the achieved CSF values were still 10 times
above the normal range. Because GAA is neurotoxic [29], a more effec-
tive reduction of CSF GAA levels may further improve clinical outcomes.
This could be particularly achieved by the use of sodium benzoate,
which crosses the blood–brain barrier and thus potentially reduces ce-
rebral GAA synthesis by removing glycine from cerebral AGAT activity
[30].
Our data suggest that early initiation of treatment favorably impacts
neurodevelopmental outcomes. Most patients with severe DD/ID were
diagnosed late (median age at treatment start 11 y), whereas those
with mild and moderate DD/ID were all diagnosed at a median age of
25 and 38 months. 2 patients who received treatments from birth/
prenatally (Patients 1 and2)were normal at 14 and41 months of age. Pa-
tient 3 who also was treated since birth was normal at 31 months [15].
Her borderline IQ at age 8 years is most likely the result of treatment in-
terruption and ongoing compliance problems. The decline in IQ observed
in this patient, suggests that therapy should be continued andmonitored,
at least throughout childhood, to preserve intellectual functions.
Despite the trend to better outcomes in early treated patients, the
median age at diagnosis and treatment start was 60 months. Only 6
children were younger than 12 months when treatment was initiat-
ed. Reasons for late diagnosis include: (1) limited awareness of this
potentially treatable condition among developmental pediatricians
and neurologists; (2) nonspecific clinical presentation (patients
may present with developmental delay and seizures only); and (3)
limited availability of diagnostic tests (urinary/plasma GAA is a spe-
cific diagnostic marker, but its determination requires a particular
method which is not universally available). (4) Single observations
suggest that urine GAA can be false negative in very young children
[16,28].
The beneficial outcomes in the early-treated patients make GAMT
deficiency an ideal candidate for NBS. GAMT deficiency is particularly
suitable because it has been confirmed in single cases [15,24] that
GAA is elevated in dried blood spots of affected newborns. Based on a
proof of concept study [31], the British Columbia NBS Program has
developed a 3-tiered screening test including a 2-tier determination of
GAA in blood spots along with GAMT sequencing in positive cases.
Over 40,000 newborns have been screened since September 2012
with good analytical performance, but without a positive result [32].
International collaborations to utilize a standardized, multi-tiered
approach to GAMT screening and data collection from a large number
of newborns within a foreseeable time period is an important step
towards implementation of GAMT newborn screening.
When interpreting the results of this study, the readermust take the
following limitations into consideration: First and foremost, the deter-
mination of the degree of intellectual impairment was based on clinical
judgment rather than formal testing in most of the patients. Although
the above defined definitions/criteria were applied by experienced cli-
nicians, one cannot rule out imprecision or bias. Second, particularly in
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might be biased in favor of treatment by the occurrence ofmild forms of
GAMTdeficiency,which are hardly predictable by genotype or biomark-
er association [1]. Third, the small number of pre-symptomatically and
early treated patients impedes statistical evaluation; thus the trend to-
wards better outcomes needs to be verified in larger patient numbers.
Data collected in this and in previous studies [1,2] do not allow
conclusions about the influence of the genotype on the phenotype and
on the ability of the various treatment strategies to modify long-term
clinical outcomes. Further experimental studies are an essential step to-
wards personalized medicine, allowing the optimal treatment strategy
for each single patient according to the molecular pathophysiology of
the individual GAMT mutations.
For most of the patients included in this survey, monitoring of bio-
markers, choice of treatment modalities and assessment of clinical out-
comes were not done systematically, rather each reflected independent
choices of the treating physicians. This lack of standardized protocols for
treatment and monitoring is inherent to rare inborn errors of metabo-
lism [33], and creates momentum among the clinicians assembled via
this survey, to develop the following consensus recommendations.
1. Diagnosis
a. Patientswith non-syndromic DD/ID should be screened for GAMT
deficiency.
b. Determination of urinary GAA and/or of plasma GAA is the
preferred screening test.
c. Diagnosis is confirmed by GAMT mutation analysis.
d. In vivo MRS of the brain is useful in the diagnostic process but not
necessary if the diagnosis has been confirmed by biomarker (GAA)
and mutation analysis. This test however could serve as a baseline
for monitoring the increase of cerebral creatine upon treatment.
e. A consistently low urinary creatinine excretion (caused by low
body creatine) and nonspecific elevations of urinary organic
acids, urinary uric acid or other urinary metabolites normalized
to creatinine, are unspecific indicators of GAMT deficiency and
should be followed up by specific diagnostic testing [16,34].
2. Treatment
a. Oral creatine supplementationwith the aimof correcting cerebral
creatine deficiency aswell as strategies to reduce accumulation of
GAA, such as high dose L-ornithine and an arginine/protein
restricted diet, are the mainstay of treatment.
b. Creatine is given as creatine-monohydrate at recommended
dosages of 400–800 mg/kg/d orally/enterally.
c. L-Ornithine supplementation is recommended at 400–800 mg/kg/d
(molecular weight = 132.16) orally/enterally. If given as L-orni-
thine–L-aspartate (molecular weight 265.26), the dosage should
be adjusted to provide amounts of L-ornithine corresponding to
the amounts given as the free form. L-Ornithine–HCl should not
be given in high dosages because it can causemetabolic acidosis [5].
d. An arginine-restricted diet, given as 0.3–0.4 g/kg/d of natural
protein (containing approximately 250 mg/kg/d of L-arginine) to-
gether with an arginine-free essential amino acid supplement to
achieve the age related DRI effectively reduces GAA levels [35,36].
e. Whether, and to what extent, a low protein diet, given as 0.8–
1.5 g/kg/d of natural protein, with or without supplementation
of an arginine-free formula, results in reduction of GAA accumula-
tion needs to be established.
f. Sodium benzoate conjugates glycine and potentially acts as an
additional mechanism to inhibit GAA production via substrate
deprivation. Its effectiveness in reducing levels of GAA needs to
be established.
g. S-adenosylmethionine (SAM), which has been tried in 1 patient
(Patient 7), could be indicated in others whose genotype suggests
a defect at the SAM binding site of GAMT.
h. Patients may also benefit from ancillary services such as speech,
occupational and physiotherapy.3. Safety
a. Ingestion of high amounts of creatine may result in the formation
of urinary crystals. Thus, supplementation should be monitored
via regular urinalysis for the presence of creatine crystals and uri-
nary tract infection. Studies are required to determine whether
pharmacologic influence of urinary pH prevents urinary crystal
formation.
b. High dose L-ornithine supplementation has been associated with
tremors and loose stools/frequent bowel movements in 2
patients reported here. L-Ornithine has a bitter taste, and this
might have a negative influence on compliance.
c. In gyrate atrophy of the choroid and retina (OAT deficiency),
permanently high plasma levels of ornithine (800–1.400 μmol/L)
are associated with retinopathy. Therefore, monitoring for
retinopathy should be considered in patients on high dose
L-ornithine supplementation and the concentrations of ornithine
in plasma should not exceed 400 μmol/L.
d. Dietary restriction of arginine could cause a reduced availability of
L-arginine for ornithine synthesis: a reduced flux of ornithine
through the urea cycle could result in hyperammonemia. There-
fore, L-ornithine supplementation (at least low dose) and regular
monitoring of plasma ammonia levels should be considered in pa-
tients who receive an arginine-restricted diet [6,7].
e. Dietary restriction of arginine raises the risk of nutritional protein
deficiency. Thus, treatment must be supervised by a metabolic
dietician and include regular monitoring of biochemical (e.g. GAA,
creatine, ornithine, arginine) and nutritional parameters (e.g.
growth, plasma pre-albumin and plasma amino acids).
4. Biochemical monitoring
a. GAA and creatine levels are biomarkers that immediately reflect
biochemical treatment effects.
b. Plasma is the preferred body fluid for monitoring GAA levels, and
should be done in 3–6 month intervals. Shorter intervals should
be done every time a new treatment modality is introduced.
Plasma GAA levels should be determined within a fixed interval
after food and L-ornithine intake (e.g. in the morning after an
overnight fast or during the day, depending on the age of the
child, 3–6 h after food intake).
c. Determination of GAA in CSF should be considered to validate the
effectiveness of treatments in the compartment, which reflects
metabolism of the brain most directly. An LP should be done in
combinationwith other procedures (e.g.MRI/MRS)which require
sedation/anesthesia.
5. Clinical monitoring
a. Brain MRI and MRS should be done to evaluate structural (e.g.
globus pallidus lesions) and chemical changes (creatine, GAA)
and repeated if clinically indicated (persistent seizures,
movement disorders, questionable compliance with treat-
ment) as decided by the treating physician.
b. Age appropriate neurodevelopmental and behavioral assessments
(ideally using formalized tests) should be considered so as to
objectively document any delayed skills and behavioral problems.
6. Steps towards evidence informed decision making
a. Overall, numerous questions regarding the evidence of the
described treatment modalities, still remain to be answered.
b. Systematic studies are needed to determine the most effective
dosages and combinations of creatine-monohydrate, L-ornithine,
sodium benzoate and dietary protein restriction to correct GAA in
plasma, CSF, and brain and optimize outcomes.
c. As an approach to achieve this goal we are planning a web-based
platform (www.gamtonline.org) including a toolbox with
standardized treatment and monitoring protocols linked to a
GAMT research database allowing the clinician to choose the
treatment strategy most applicable to the individual patient and
to longitudinally monitor a minimum set of biomarkers and
clinical outcomes.
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on cellular pathophysiology as well as new ways i.e. pharmaco-
logical inhibition of AGAT, to prevent GAA toxicity.Acknowledgments
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